Background: Accumulating evidence has revealed that an increasing number of microRNAs (miRNAs) are dysregulated in papillary thyroid cancer (PTC) and that their dysregulation plays an important role in PTC onset and progression. Reportedly, miRNA-564 (miR-564) is downregulated in several types of human cancer. However, its expression profile and specific functions in PTC remain unclear to date. Methods: In this study, we used reverse transcription-quantitative polymerase chain reaction to detect miR-564 expression in PTC tissues and cell lines. Further, the regulatory roles of miR-564 in the malignant development of PTC in vitro and in vivo were examined using a series of functional experiments. In addition, the possible underlying mechanisms and signaling pathways involved were investigated. Results: We demonstrated that miR-564 expression markedly decreased in PTC tissues and cell lines, and this decrease correlated with the lymph node metastasis and tumor-nodemetastasis stage. miR-564 upregulation significantly inhibited cell proliferation, migration, and invasion and induced cell apoptosis in vitro as well as hindered tumor growth in vivo. Furthermore, astrocyte-elevated gene-1 (AEG-1) was identified as a direct target gene of miR-564 in PTC cells. Its expression was upregulated and inversely correlated with miR-564 expression in clinically PTC tissues. Additionally, the silencing of AEG-1 expression could imitate the action of miR-564 overexpression in PTC cells. Remarkably, the restoration of AEG-1 expression partially abolished the tumor-suppressing effects induced by a miR-564 upregulation in PTC cells. Ectopic miR-564 expression deactivated the PTEN/Akt pathway in PTC cells in vitro and in vivo. Conclusion: Overall, the findings of the current study suggest that miR-564 is a tumorsuppressive miRNA that exerts crucial roles in the development and progression of PTC. Therefore, this miRNA might be a promising candidate target in the anticancer treatment of patients with PTC.
Introduction
Thyroid cancer, originating from follicular or parafollicular thyroid cells, is the most common endocrine malignancy. 1 Globally, approximately 300,000 novel thyroid cancer, accounting for more than 80% of all thyroid cancer cases. 4 Genetic and epigenetic alterations have been shown to play a crucial role in the genesis and development of PTC; however, the detailed molecular mechanisms underlying these changes remain poorly characterized. 5, 6 The primary therapeutic strategies currently employed against PTC, including surgical resection, radioiodine therapy, and adjuvant long-term thyrotropin suppression therapy, result in an excellent prognosis in the vast majority of patients; however, recurrence and metastasis are frequently associated with poor clinical outcomes. 7, 8 Therefore, the mechanisms involved in the pathogenesis of PTC need to be clarified to aid in the development of improved therapeutic approaches for patients with PTC. microRNAs (miRNAs) are a group of endogenous, singlestranded, and non-coding 18-24 nucleotide-long RNA molecules. 9 So far, more than 1,400 miRNAs have been identified in the human genome. 10 miRNAs are capable of regulating gene expression at the transcriptional or posttranscriptional level by partially base pairing with the 3′-untranslated regions (3′-UTRs) of their target genes, triggering mRNA degradation, and/or transcriptional silencing.
11
Aberrations in miRNA expression have been reported in nearly all types of human cancer, suggesting that miRNAs participate in carcinogenesis and cancer progression. [12] [13] [14] Promising studies have discovered that various miRNAs are dysregulated in PTC and exert tumor-suppressive or oncogenic roles. [15] [16] [17] miRNA dysregulation is implicated in various biological processes and plays a crucial role in the oncogenicity of PTC. 18, 19 Therefore, further investigation into the specific roles played by miRNAs in PTC may facilitate the identification of effective targets for the treatment of patients with this disease. miR-564 is reportedly downregulated in several types of human cancer and involved in carcinogenesis and cancer progression. [20] [21] [22] [23] [24] [25] However, its expression profile and specific functions in PTC remain unclear as yet. Accordingly, the purpose of the current study was to determine miR-564 expression in PTC and assess its clinical significance. In addition, the expression profile of AEG-1 in PTC tissues was also determined. The effects of miR-564 on the aggressive behavior in PTC were investigated using a series of in vitro and in vivo experiments. Furthermore, the possible underlying mechanisms and signaling pathways involved were investigated. This study provides novel insights into the crucial role of the miR-564/AEG-1/PTEN/Akt pathway in the development and progression of PTC.
Materials and methods

Ethical statement
The experimental protocols of this study were approved by the Ethics Committee of The Third People's Hospital of Linyi (170011). This study was conducted in accordance with the principles of the Declaration of Helsinki, and written informed consent was provided by all patients enrolled in the study.
Tissue samples and cell lines
Paired PTC and normal adjacent tissue samples were obtained from 47 patients who underwent surgical resection at The Third People's Hospital of Linyi. None of these patients received any preoperative therapy, including radioiodine therapy, or chemotherapy. Following collection, all tissues were rapidly frozen in liquid nitrogen and then stored at −80°C for later use. In total, three human PTC cell lines (TPC-1, BCPAP, and HTH83) and a normal human thyroid cell line (HT-ori 3) were bought from the American Type Culture Collection (Manassas, VA, USA). All cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) containing 10% heat-inactivated fetal bovine serum (FBS; Hyclone, Logan, UT, USA) and 1% antibiotic/antimycotic solution (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). All cell lines were maintained at 37°C in a humidified incubator supplied with 5% CO 2 .
Cell transfection miR-564 mimics and negative control miRNA mimics (miR-NC) were constructed by Shanghai GenePharma Co., Ltd. (Shanghai, China). Astrocyte-elevated gene-1 (AEG-1), small interfering RNA (siRNA), and scrambled negative control siRNA were obtained from Guangzhou RiboBio Biotechnology Co., Ltd. (Guangzhou, China). The full length of AEG-1 lacking 3′-UTR was amplified by Shanghai GenePharma Co., Ltd., and inserted into a plasmid, pcDNA3.1, referred to as pc-AEG-1. Cells were inoculated into six-well plates at a density of 6×10 5 cells/well 24 hrs prior to transfection. Transient transfection was performed using Lipofectamine ® 2000 reagent (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's instructions. Then, the transfected cells were harvested following different incubation times and used for subsequent functional assays.
Isolation of total RNA and reverse transcription-quantitative polymerase chain reaction (RT-qPCR)
Total RNA was extracted from tissue specimens and cultured cells using TRIzol ® (Thermo Fisher Scientific, Inc.).
Total RNA was reverse transcribed into complementary DNA (cDNA) using a miScript Reverse Transcription kit (Qiagen GmbH, Hilden, Germany). To quantify the miR-564 expression levels, RT-qPCR was conducted using a miScript SYBR Green PCR kit (Qiagen GmbH, Hilden, Germany). U6 small nuclear RNA was used as an endogenous control for miR-564. For the quantification of AEG-1, first-strand cDNA was prepared from total RNA using a RevertAid™ First-Strand cDNA Synthesis kit (Thermo Fisher Scientific, Inc.), followed by qPCR with an SYBR Green PCR Master mix (TaKaRa, Dalian, China). AEG-1 expression was normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Further, relative gene expression was calculated using the 2 −ΔΔCq method. 26 
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay
MTT assay was performed to determine cell proliferation, in accordance with the manufacturer's instructions. In brief, transfected cells were harvested following 24-hr incubation and resuspended in DMEM supplemented with 10% FBS. A total of 200 µL culture medium containing 3×10 3 cells was placed in each well of a 96-well plate.
Cell proliferation was determined at four time points: 0, 24, 48, and 72 hrs following incubation. Following the addition of 20 µL MTT solution (5 mg/mL; SigmaAldrich) to each well, the samples were incubated at 37°C with 5% CO 2 for an additional 4 hrs. Next, the culture medium was carefully removed, and formazan crystals formed were dissolved in dimethyl sulfoxide. Optical density (OD) at a wavelength of 490 nm was measured using an ELISA microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA).
Cell apoptosis assay
To analyze apoptosis, transfected cells were collected at 48 hrs following transfection with trypsin (Gibco; Thermo Fisher Scientific, Inc.) and washed thrice with an ice-cold phosphate buffer solution (Gibco; Thermo Fisher Scientific, Inc.) at 4°C. The apoptosis rate was estimated using an Annexin V-fluorescein isothiocyanate apoptosis detection kit (Biolegend, San Diego, CA, USA). Briefly, the cells were resuspended in 100 µL of 1×binding buffer and then stained with 5 µL Annexin Vfluorescein isothiocyanate and 5 μL propidium iodide. Following 20-min culturing at room temperature in the absence of light, apoptotic cells were measured by flow cytometry (FACScan™, BD Biosciences, Franklin Lakes, NJ, USA).
Transwell assay
Transwell chambers (8-μm pores; BD Biosciences, San Jose, CA, USA) were used for migration analysis. Briefly, 5× 10 4 transfected cells were suspended in 200
μL FBS-free DMEM medium and seeded into the top compartment of a transwell chamber. Lower compartments were filled with 600 μL DMEM medium supplemented with 10% FBS. Following 24-hr incubation at 37°C, the non-traversed cells retained in the underside of the top chamber were gently wiped away. Next, migrated cells were fixed in 100% methanol and stained with 0.1% crystal violet. Invasion analyses were performed using the same procedure as for migration assay, except that the chambers were precoated with Matrigel (BD Biosciences). The number of migrated and invaded cells was counted in five randomly selected fields per chamber using a light microscope (Olympus, Tokyo, Japan).
In vivo tumor xenograft model 
Bioinformatics analysis and luciferase reporter assay
Targetscan (www.targetscan.org/vert_71) and MiRanda (http://www.microrna.org) were used to search the putative target genes of miR-564. Wild-type (wt) 3′-UTR of AEG-1 containing predicted miR-564 binding sites was amplified by Shanghai GenePharma Co., Ltd., and inserted into the psiCHECK-2 luciferase expression vector (Promega Corporation, Madison, WI, USA) to generate psiCHECK-wt-AEG-1-3ʹ-UTR. Similarly, mutant (mut) AEG-1 3′-UTR was cloned into the psiCHECK-2 luciferase expression vector to generate psiCHECK-mut-AEG-1-3ʹ-UTR. The chemically synthesized reporter vectors were co-transfected with miR-564 or miR-NC into the cells using Lipofectamine ® 2000 reagent. After 24 hrs, transfected cells were collected and prepared to measure their firefly and Renilla luciferase activities using a Dual-Luciferase Reporter Assay System (Promega). Renilla luciferase activity was normalized to that of firefly luciferase.
Western blot analysis
Radioimmunoprecipitation assay lysis buffer (SigmaAldrich; Merck KGaA, Darmstadt, Germany) containing protease inhibitors (Roche Applied Science, Madison, WI, USA) was used to isolate total protein from cells or tissues. The quantification of total protein was performed using a bicinchoninic acid protein assay kit (Cwbiotech, Beijing, China). Equivalent quantities of total protein were separated by 10% SDS-PAGE and transferred to polyvinylidene difluoride membranes (Beyotime Institute of Biotechnology, Haimen, China). Then, the membranes were blocked for 2 hrs at room temperature with non-fat powdered milk diluted in Tris-buffered saline containing 0.1% Tween 20 (TBST), followed by an overnight incubation with primary antibodies at 4°C. Next, the membranes were washed thrice with TBST prior to 2-hr incubation at room temperature with horseradish peroxidase-conjugated secondary antibody (ab6789 and ab6721; 1:5000 dilution; Abcam, Cambridge, MA, USA). The blots were observed using an Enhanced Chemiluminescence Detection System (Pierce; Thermo Fisher Scientific, Inc.). The following antibodies were used for Western blot analysis: mouse anti-human AEG-1 monoclonal primary antibody (sc-517220; 1:1000 dilution; Santa Cruz Biotechnology, CA, USA), rabbit anti-human monoclonal PTEN (ab170941; 1:1000 dilution; Abcam), mouse anti-human monoclonal p-Akt (sc-514032; 1:1000 dilution; Santa Cruz Biotechnology), mouse anti-human monoclonal Akt (sc-81434; 1:1000 dilution; Santa Cruz Biotechnology), and mouse anti-human monoclonal GADPH antibody (ab125247; 1:1000 dilution; Abcam). GAPDH was used as a loading control.
Statistical analysis
Statistical Product and Service Solutions version 17.0 (IBM Corporation, Armonk, NY, USA) was employed to perform statistical analyses. All results are presented as means ± standard deviation (SD). The correlation between miR-564 expression and clinicopathological parameters in patients with PTC was evaluated using chi-square test. Spearman's correlation analysis was used to assess the expression correlation between miR-564 and AEG-1 mRNA levels in PTC tissues. Further, Student's t-test and one-way analysis of variance with Bonferroni test were used to analyze differences between two and multiple groups, respectively. P<0.05 was considered statistically significant for all analyses.
Results
miR-564 is downregulated in PTC tissues and cell lines
To clarify the expression profile of miR-564 in PTC, we first examined miR-564 expression in 47 pairs of PTC tissues and normal adjacent tissues. The data obtained from RT-qPCR analysis indicated that the expression levels of miR-564 were lower in PTC tissues than in normal adjacent tissues ( Figure 1A , P<0.05). Next, we explored the association between miR-564 expression and clinicopathological parameters to reveal the clinical value of miR-564 in patients with PTC. Low miR-564 expression correlated with the lymph node metastasis (P=0.002) and tumor-nodemetastasis (TNM) stage (P=0.008) in patients with PTC (Table 1) . However, the correlations between miR-564 and other clinicopathological characteristics were not significant (all P>0.05). Meanwhile, miR-564 expression was found to be significantly downregulated in all three tested PTC cell lines (TPC-1, BCPAP, and HTH83) compared with the expression in a normal human thyroid cell line (HT-ori3; Figure 1B , P<0.05). These results suggested that a reduction in miR-564 expression may be closely related to the development and progression of PTC.
miR-564 upregulation suppresses cell proliferation, migration, and invasion and induces cell apoptosis in PTC in vitro AEG-1 is a direct target gene of miR-564 in PTC cells miRNA mainly functions through direct binding to the 3′-UTR of its target gene, resulting in mRNA degradation and/ or transcriptional silencing. 11 To explore the mechanisms associated with the tumor-suppressing roles of miR-564, bioinformatics analysis was conducted to predict the potential target of miR-564. The 3′-UTR region of AEG-1 was predicted to be a putative binding site for miR-564 because it harbored the regions matching the miR-564 seed sequences ( Figure 3A) . Accordingly, AEG-1 was selected for further validation because this gene has been implicated in the modulation of PTC occurrence and development. [27] [28] [29] Luciferase reporter assay was employed to determine whether the 3′-UTR of AEG-1 could be directly targeted by miR-564 in PTC cells. As shown in Figure 3B , enforced miR-564 expression significantly decreased luciferase activity in the wt 3′-UTR of AEG-1 in TPC-1 and HTH83 cells (P<0.05); however, a mutation of the miR-564 binding site in the 3′-UTR of AEG-1 abrogated the luciferase response to miR-564. Furthermore, the effect of miR-564 on endogenous AEG-1 expression in PTC cells was investigated. TPC-1 and HTH83 cells transfected with mIR-564 mimics exhibited significantly decreased AEG-1 expression at the mRNA ( Figure 3C , P<0.05) and protein ( Figure 3D , P<0.05) levels compared with that in the cells transfected with miR-NC. These results suggest that AEG-1 is a novel target of miR-564 in PTC cells.
miR-564 is negatively correlated with AEG-1 in PC tissues
Next, we investigated AEG-1 expression in PTC tissues and explored the expression relationship between miR-564 and AEG-1. RT-qPCR revealed that the expression level of Figure 8A and B, P<0.05). Additionally, the tumor weight in the miR-564 mimics group significantly decreased compared with that in the miR-NC group ( Figure 8C , P<0.05). The data from RTqPCR proved that miR-564 expression were still upregulated in the excised tumor xenografts derived from the miR-564 mimics-transfected TPC-1 cells ( Figure 8D , P<0.05). Western blot analysis showed that the expression of AEG-1 and p-Akt was downregulated and that of PTEN was upregulated in the miR-564 mimics group compared with that in the miR-NC group ( Figure 8E ). These results suggest that miR-564 overexpression restrained the tumor growth of PTC cells in vivo by regulating the AEG-1/ PTEN/Akt pathway.
Discussion
In the past few years, several studies have focused on the expression profiles and biological roles of miRNA in PTC. 17, 33, 34 An increasing number of miRNAs have been found to be dysregulated in PTC, and their dysregulation is believed to have important impacts on the formation and progression of PTC via a negative regulation of their target genes implicated in cellular biological behaviors. 19, 35, 36 Hence, further investigation of the detailed roles of specific miRNAs in PTC might facilitate the identification of more effective targets for the treatment of patients with PTC. In the present study, to the best of our knowledge, we detected miR-564 expression levels in PTC tissues and cell lines for the first time. Next, we explored the biological roles of miR-564 upregulation in PTC progression and clarified its associated molecular mechanisms and downstream signaling pathway. Our study revealed a significant role of the miR-564/AEG-1/ PTEN/Akt pathway in suppressing the development of PTC cells in vitro and in vivo. miR-564 is downregulated in osteosarcoma tissues and cell lines. 20, 21 Decreased miR-564 expression is strongly linked to clinical stages and distant metastases in patients with osteosarcoma. Patients with osteosarcoma having low miR-564 expression exhibit shorter overall survival and disease-free survival than those with high miR-564 expression. Additionally, miR-564 is identified as an independent poor prognostic factor in patients with osteosarcoma.
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Decreased miR-564 expression is observed in hepatocellular carcinoma, and this decrease is substantially associated with tumor size, tumor number, and venous invasion. cancer, 23 gastric cancer, 24 glioblastoma, 25 breast cancer, 37 lung cancer, 38 and chronic myeloid leukemia. 39 However, the current knowledge about the expression profile of miR-564 in PTC is limited. RT-qPCR analysis indicated that miR-564 expressed at low levels in PTC tissues and cell lines. miR-564 downregulation substantially correlated with lymph node metastasis and TNM stage in patients with PTC. These findings suggest that miR-564 is a potential prognosis predictor in patients with PTC.
miR-564 has been demonstrated to be a tumorsuppressive miRNA in many types of human malignancy. For instance, ectopic miR-564 expression attenuates proliferation and promotes apoptosis in osteosarcoma cells. 21 Resumption of miR-564 expression inhibits hepatocellular carcinoma cell proliferation, migration, and invasion in vitro and decreases tumor growth in vivo. 22 Upregulation of miR-564 suppresses cell growth and metastasis and induces cell cycle arrest in prostate cancer. 23 miR-564 restoration restricts the proliferative and invasive capacities of glioblastoma cells in vitro. 25 Moreover, miR-564 exerts a tumor-suppressing role in the progression of breast 37 and lung 38 cancers. Nevertheless, the functional role of miR-564 in the development of PTC remains unclear at present. In this study, a series of experiments demonstrated that miR-564 could inhibit cell proliferation, migration, and invasion of PTC cells in vitro; induce cell apoptosis in vitro; and hinder tumor growth in vivo. These findings suggest that miR-564 is a promising target in the treatment of patients with PTC.
Several genes, including Akt 21 in osteosarcoma, GRB2 in hepatocellular carcinoma, 22 MLLT3in prostate cancer, 23 E2F3 in gastric cancer, 24 and TGF-β1 in glioblastoma, 25 have been identified as direct targets of miR-564. To investigate this, we attempted to clarify the direct target gene involved in the antitumor role of miR-564 in PTC cells. AEG-1, also known as metadherin, was found to be a novel direct downstream target of miR-564 in PTC cells. It is located on chromosome 8q22 and was first discovered in human fetal astrocytes in 2002. 40 AEG-1 is highly expressed in PTC, and high AEG-1 expression is related to tumor size, lymph node metastasis, and distant metastasis. 27 In addition, high expression levels of AEG-1 are closely correlated with recurrence-free survival in PTC patients. 27 Cox regression analysis identifies AEG-1 expression as an independent prognostic indicator for recurrence-free survival in patients with PTC. 27 Functionally, AEG-1 has been acknowledged as an important regulator of PTC genesis and development by affecting a number of aggressive behaviors. 28, 29 The current study demonstrated that miR-564 upregulation inhibited the oncogenicity of PTC cells in vitro and in vivo by directly targeting AEG-1. Hence, miR-564 restoration-mediated silencing of AEG-1 expression might represent an attractive therapeutic strategy for patients with PTC.
Conclusion
This study is the first to provide evidence that miR-564 expression is downregulated in PTC and that this downregulation exhibits a significant association with lymph node metastasis and TNM stage in patients with PTC. Further, miR-564 exerts its tumor-suppressing roles in PTC, at least partially, by directly targeting AEG-1 and deactivating the PTEN/Akt pathway. This newly identified miR-564/AEG-1PTEN/Akt pathway offers novel insights into the molecular mechanisms underlying PTC pathogenesis and suggests that this signaling pathway might be developed as a promising target for the management of patients with this malignant tumor. However, there are two limitations to the current study. The correlation between miR-564 and the prognosis of PTC patients was not analyzed. In addition, the effect of miR-564 upregulation on in vivo tumor metastasis was not examined. These two limitations will be resolved in future experiments.
